SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 16.19 |
Enterprise Value ($M) | -7.55 |
Book Value ($M) | 22.10 |
Book Value / Share | 3.32 |
Price / Book | 0.73 |
NCAV ($M) | 22.10 |
NCAV / Share | 3.32 |
Price / NCAV | 0.73 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.73 |
Return on Assets (ROA) | -0.49 |
Return on Equity (ROE) | -0.64 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 10.66 |
Current Ratio | 10.66 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 24.39 |
Assets | 24.39 |
Liabilities | 2.29 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 65.30 |
Operating Income | 25.44 |
Net Income | 17.78 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -50.47 |
Cash from Investing | 49.14 |
Cash from Financing | -11.87 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Tang Capital Partners Lp | 4.90 | -9.69 | |
13G/A | Vanguard Group Inc | 5.85 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
765 | 4,849 | 15.78 | |
220 | 9,501 | 2.32 | |
480 | 32,691 | 1.47 | |
2,550 | 12,825 | 19.88 | |
(click for more detail) |
Similar Companies | |
---|---|
MBIO – Mustang Bio, Inc. | MBRX – Moleculin Biotech, Inc. |
ME – 23andMe Holding Co. | MIRA – MIRA Pharmaceuticals, Inc. |
MLTX – MoonLake Immunotherapeutics |